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Depression is the fourth leading cause of 
disability and disease worldwide. WHO 
projections indicate that depression will be 
the highest ranked cause of disease burden 
in the middle- and high-income countries 
by the year 2030 [1].
Drugs that increase the synaptic avail-
ability of monoamines, including tricyclic 
antidepressants, selective serotonin reuptake 
inhibitors, serotonin and norepinephrine 
reuptake inhibitors, and dopamine reuptake 
inhibitors, have been used to treat depres-
sion for more than 50 years. However, these 
drugs have significant limitations, includ-
ing a long time lag for therapeutic response 
(weeks to months), low response rates and 
side effects serious enough to induce dis-
continuation in nearly 20% of patients. 
Moreover, the delayed response is suggestive 
of an involvement in antidepressant thera-
peutic action of slow-onset adaptations in 
downstream signaling pathways regulating 
neuroplasticity and cellular resilience [2,3].
Recent growing evidence suggests that 
glutamatergic neurotransmission, the major 
excitatory system in the brain, plays a criti-
cal role in the pathophysiology and treat-
ment of neuropsychiatric disorders. The 
glutamatergic system is interconnected with 
GABAergic and monoaminergic pathways, 
and it has been shown that approximately 
80% of neurons in the neocortex are excita-
tory glutamatergic neurons [4]. In the last 
several years, a number of clinical and 
preclinical studies demonstrated that mala-
daptive changes in excitatory/inhibitory cir-
cuitry, particularly in glutamate homeo stasis 
and neurotransmission, have a primary role 
in mood and anxiety disorders.
First, it has been shown that glutamate 
levels are increased in plasma and in post-
mortem samples of frontal cortex from 
patients with major depressive disorder, 
and antidepressants restore normal plasma 
glutamate levels [5,6]. Abnormalities in total 
brain levels of glutamate and its metabo-
lite glutamine were also investigated in 
vivo using proton magnetic resonance 
spectroscopy. While results varied, a large 
majority of studies have provided evidence 
of reduced glutamate metabolite levels in 
the frontal cortex and cingulate regions 
of depressed patients during depressive 
episodes (reviewed in [7]). Interestingly, 
glutamate metabolite levels normalize dur-
ing clinical remission, suggesting a patho-
physiological importance during active 
episodes of major depression. Moreover, a 
recent work showed that the reduction of 
glutamate levels in the anterior cingulate 
cortex of depressed patients normalized 
with electroconvulsive therapy treatment 
and was associated with  clinically assessed 
therapeutic response [8].
Moreover, several postmortem studies 
have shown altered mRNA and protein 
expression of glutamate receptors (N-methyl-
d-aspartate receptors, α-amino-3-hydroxy- 
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5-methyl-4-isoxazolepropionic acid receptors and metabotropic 
glutamate receptors [mGluRs]) in select brain areas from depressed 
individuals, suggesting that dysregulation of glutamatergic 
receptor signaling is likely to be associated with the disorder [9].
Furthermore, expression of the glial excitatory amino acid 
transporters, responsible for glial glutamate reuptake, was found 
to be reduced in individuals with major depression, suggesting 
reduced extracellular glutamate clearance [10]. Since glia partici-
pates in the uptake, metabolism and recycling of glutamate, it 
was hypothesized that a reduction of glial activity may account 
for the alterations in glutamate neurotransmission observed in 
depression. Interestingly, neuropathological studies in postmor-
tem brains from patients with major depression reported consist-
ent evidence for reduced glial cell number and/or density in the 
brain regions with glutamatergic predominance, including orbital, 
anterior cingulate, subgenual and dorsolateral prefrontal cortices 
[11]. Similarly, brain morphometric studies of patients with major 
depression have demonstrated volumetric reduction of prefrontal 
regions, especially the orbital frontal cortex, the anterior cingulate 
cortex and the subgenual cingulate cortex, and of hippocampus, 
brain regions closely associated with stress response and emo-
tional/cognitive processing [12]. Interestingly, volumetric reduc-
tions and the decrease of glial cell number and density observed in 
depressed subjects are localized in the same brain areas, suggesting 
a possible correlation between these phenomena.
This hypothesis has also received support from numerous pre-
clinical studies reporting brain structural remodeling in animal 
models of depression. Animal models are widely used to study 
the pathophysiology of mood disorders. Since behavioral stress is 
recognized as a main risk factor for mood and anxiety disorders, 
most animal models of depression are based on stress exposure. 
Subjecting experimental animals to behavioral stress is a clas-
sical way of inducing measurable neuroendocrine, behavioral, 
neurochemical and morphological changes, resembling those 
observed in depressed subjects. Animal studies suggest a role for 
glucocorticoid signaling, activated by stressors in both rodents 
and humans and altered in depressed individuals, and the con-
sequent enhancement of glutamate release in the morphological/
functional changes induced by stress. Indeed, a number of studies 
reported a rapid, transient and marked increase of extracellular 
glutamate in different areas, including the hippocampus, amyg-
dala and prefrontal cortex of rats subjected to different stressors 
or to treatment with corticosterone (the main stress hormone 
in rodents; reviewed in [4,13]). It was also demonstrated, using 
different methodologies, that the rapid increase of extracellu-
lar glutamate levels is related to increased depolarization-evoked 
release, mediated by corticosterone membrane-located receptors 
(mineralocorticoid receptor in hippocampus, glucocorticoid in 
prefrontal and frontal cortex) coupled to nongenomic (protein 
synthesis-independent) mechanisms [14,15]. Chronic antidepres-
sants nearly or completely abolish the stress-induced upregulation 
of glutamate release in cortical areas, suggesting that this drug 
effect may be a relevant component of the therapeutic action of 
antidepressants.
Moreover, it was shown that chronic exposure to behavioral 
stress induces atrophy, retraction and simplification of dendritic 
arbor in both hippocampal CA3 area and medial prefrontal cor-
tex, changes that are reversible both after the cessation of stress 
and antidepressant treatment [4,16].
The simplification of dendritic arbor induced in the hippo-
campus and medial prefrontal cortex of stressed rats is considered, 
together with the loss of glial cells, one of the likely mechanisms 
accounting for the volumetric changes registered in the hippo-
campus and prefrontal cortex areas of humans with major depres-
sion. Indeed, while changes in the size and shape of dendritic 
shafts and spine density are typical physiological mechanisms of 
activity-dependent synaptic plasticity, higher and sustained extra-
cellular concentrations of glutamate may cause dendrite retraction 
and impair glial and neuronal function.
All these preclinical and clinical lines of evidence have pro-
vided the background for the formulation of a new hypothesis for 
the etiopathogenesis of depression: the glutamate hypothesis of 
depression [4,17]. In this conceptual framework, a sustained gluta-
mate accumulation, caused by alterations of glutamate release, 
clearance and metabolism, in selected brain areas associated with 
cognitive-emotional behaviors and mood regulation, is recognized 
as the cause of the structural/functional changes and impaired 
synaptic activity in these regions.
Further support for this hypothesis comes from a number 
of clinical studies showing rapid and prolonged antidepressant 
action of glutamate receptor antagonists, particularly ketamine. 
Ketamine, a noncompetitive N-methyl-d-aspartate receptor 
antagonist, is used as a standard anesthetic agent at doses as high 
as 2 mg/kg. Intriguingly, different studies have reported a robust, 
rapid (within 2 h) and sustained (~1 week) antidepressant effect 
in treatment-resistant patients with major depressive disorder of 
a single infusion of ketamine at subanesthetic doses (0.5 mg/kg 
[18,19]). However, limitations in the clinical use of ketamine due 
to its poor safety profile (psychotomimetic effects, cognitive 
impairments, tolerance) impede a widespread application of 
this molecule in the treatment of depression. For this reason, 
a number of drugs affecting glutamatergic neurotransmission 
(selective NR2B antagonists, positive modulators of α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor and 
mGluR ligands) are in development as potential antidepressant 
agents. In particular, accumulating recent preclinical evidence 
“…simplification of dendritic arbor … is considered, 
together with loss of glial cells, one of the likely 
mechanisms accounting for the volumetric changes 
registered in hippocampus and prefrontal cortex 
areas of humans with major depression.”
“…brain morphometric studies of patients with 
major depression have demonstrated volumetric 
reduction of prefrontal regions … brain regions 
closely associated with stress response and 
emotional/cognitive processing.”
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has shown a consistent antidepressant effect of group II mGluR 
(mGluR2/3) ligands (administered in combination with exist-
ing antidepressants) and Group III mGluR selective agonists 
(mainly of mGluR7 and mGluR8) or allosteric modulators (of 
mGluR4 [20]).
Although early-phase clinical trials of drugs are now in progress, 
larger randomized clinical trials are needed to establish the poten-
tial therapeutic efficacy of these drugs, based on the glutamate 
hypothesis of depression.
Moreover, the dampening action of chronic antidepressants 
on the stress-induced upregulation of glutamate release, 
observed in preclinical models [15], suggests a new putative 
line of drug development directly targeted at the molecular 
mechanisms regulating glutamate release [4,13]. In this context, a 
pharmacological modulation of presynaptic release of glutamate 
might provide a means of attenuating exaggerated or inadequate 
stress response in mood/anxiety disorders. On the other hand, 
since several antidepressants tested, endowed with distinct primary 
mechanisms, are all able to abolish the effects of stress on glutamate 
release [15], we hypothesize that this could be a selective property 
of antidepressants related with their therapeutic action. For this 
reason, we propose the measurement of the preventive effect of 
drugs on stress-induced glutamate release as a functional test to 
assay molecules with antidepressant/anxiolytic action.
There are several challenges that remain to be addressed by 
novel antidepressant therapies. Ideal new drugs should obtain a 
rapid and sustained remission of symptoms and have minimal 
cognitive side effects. The rapid action of glutamate receptor 
antagonists is certainly a fascinating and promising feature for 
third-generation antidepressants, allowing for immediate clinical 
effects with possibly higher rates of remission.
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“…a sustained glutamate accumulation, caused by 
alterations of glutamate release, clearance and 
metabolism, in selected brain areas associated with 
cognitive-emotional behaviors and mood regulation, 
is recognized as the cause of the structural/
functional changes and impaired synaptic activity…”
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